Hi Dr T, can you please clarify a little on the timing of this...

Hi Dr T, can you please clarify a little on the timing of this trial in 2024 and how we may expect the year to play out. Notwithstanding unforeseen delays, of which we hope there are none. Specifically interested in timing/opportunities for share price inflection points.

***

To lay it out for my own understanding more than anything, RC220 is expected to be available Q1 2024:


***

Then the GLP toxicology and safety package will be finished late Q 2 2024 so by mid year.


***

First patient is then to be dosed some time in 2024 (do we have anything more specific on that? It is quite broad but I expect we will find out more soon.....) . Then as per above post, safety data only from that first dosing is what we are likely to see this year - from which I infer it will probably be late 2024 for that data.

What are the steps that Race have to take between the delivery of the GLP package mid year and the safety data by end of 2024? At the risk of sounding impatient, why does it take so long to progress through the stages?

Is it all just waiting on ethics approval in that period, or are there other steps? I remember from a previous post that you said ethics approval could be applied for BEFORE the GLP package was finished (in a draft format) to minimise waiting time on that.

Once the first patient IS dosed, what is the period of time for that phase of the dosing/testing? And yes it will definitely be very significant for Race to have that first bit go smoothly (which I have confidence in based on all the prior testing that has been done)!

I understand we are likely to have some other notable/exciting news through the year to help us along and get that share price moving up, but I was wondering about this trial specifically.

Thanks in advance